Topical Minoxidil for Breast Reconstruction
This study is looking at whether applying minoxidil to the skin can improve blood flow (perfusion) and tissue health (viability) in breast tissue flaps during breast reconstruction surgery. You might be able to join if you are a woman over 18 with a genetic risk for cancer, having a bilateral prophylactic mastectomy (removal of both breasts to prevent cancer) with immediate reconstruction. The study is testing minoxidil against a placebo (inactive substance) to see if it helps. The main goals are to see how easy it is to recruit and keep participants, and how well participants follow the study instructions. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 25 women. Each participant will have one breast randomly assigned to receive minoxidil and the other to receive a placebo, acting as an internal control.
- What's involved
- You would apply minoxidil or a hair mousse daily for 14 days before surgery. The study will assess your adherence to this protocol for 90 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 90 days to assess retention and adherence to the protocol.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Brett Phillips, MD · PRINCIPAL_INVESTIGATOR · Duke University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility, as measured by recruitment rateDay 1
Rate of study participation from eligible patients undergoing bilateral risk-reducing mastectomy with tissue expander-based implant reconstruction
- Feasibility, as measured by retention rate90 days
Retention of enrolled participants until the clinical endpoint
- Feasibility, as measured by rate of participant adherence to the protocol90 days
Rate of adherence to the treatment protocol